Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$382M |
| 2 |
Pfizer
PFE
|
+$266M |
| 3 |
EA
Electronic Arts
EA
|
+$240M |
| 4 |
Eli Lilly
LLY
|
+$221M |
| 5 |
Colgate-Palmolive
CL
|
+$216M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Booking.com
BKNG
|
+$358M |
| 2 |
Comcast
CMCSA
|
+$263M |
| 3 |
Meta Platforms (Facebook)
META
|
+$258M |
| 4 |
AET
Aetna Inc
AET
|
+$257M |
| 5 |
Tesla
TSLA
|
+$189M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.13% |
| 2 | Technology | 13.55% |
| 3 | Financials | 11.85% |
| 4 | Consumer Staples | 10.18% |
| 5 | Industrials | 9.44% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
UCB
351
United Community Banks
UCB
$4.36B
| $54.2M | 0.07% |
1,948,368
-129,800
| -6% | -$3.51M |
|
352
Pricesmart
PSMT
$5.4B
| $53.8M | 0.07% |
614,100
+50,300
| +9% | +$4.42M |
|
353
WSFS Financial
WSFS
$4.15B
| $53.3M | 0.07% |
1,174,414
+39,600
| +3% | +$1.81M |
|
354
Qiagen
QGEN
$8.79B
| $53.3M | 0.07% |
1,497,768
+69,135
| +5% | +$2.33M |
|
355
Vornado Realty Trust
VNO
$7.24B
| $53.3M | 0.07% |
701,501
+404,870
| +136% | +$31.4M |
|
356
REX American Resources
REX
$1.43B
| $52.8M | 0.07% |
3,279,600
-132,000
| -4% | -$2.09M |
|
|
SINA
357
DELISTED
Sina Corp
SINA
| $52.6M | 0.07% |
+619,100
| New | +$52.1M |
|
358
Newell Brands
NWL
$2.57B
| $52.5M | 0.07% |
979,127
-281,700
| -22% | -$14.3M |
|
|
BT
359
DELISTED
BT Group plc (ADR)
BT
| $52.2M | 0.07% |
2,690,100
-455,000
| -14% | -$8.97M |
|
360
GoDaddy
GDDY
$11.4B
| $52.1M | 0.07% |
1,227,600
+694,900
| +130% | +$27.8M |
|
361
Abbott
ABT
$190B
| $51.8M | 0.07% |
1,065,566
-2,058,700
| -66% | -$93.2M |
|
362
FirstService
FSV
$6.2B
| $51.4M | 0.07% |
803,500
-9,700
| -1% | -$602K |
|
|
WP
363
DELISTED
Worldpay, Inc.
WP
| $51.3M | 0.07% |
+809,500
| New | +$50.8M |
|
|
BRSL
364
Brightstar Lottery PLC
BRSL
$2.03B
| $51.1M | 0.07% |
2,791,500
+1,428,700
| +105% | +$29.2M |
|
|
RPAI
365
DELISTED
RETAIL PROPERTIES OF AMERICA, INC.
RPAI
| $51M | 0.07% |
4,173,100
-205,302
| -5% | -$2.69M |
|
|
CARB
366
DELISTED
Carbonite Inc
CARB
| $50.5M | 0.06% |
2,317,700
+131,300
| +6% | +$2.7M |
|
367
Plains All American Pipeline
PAA
$16.3B
| $50.5M | 0.06% |
1,921,614
+1,728,100
| +893% | +$47.8M |
|
|
VALE.P
368
DELISTED
Vale S A
VALE.P
| $50.5M | 0.06% |
6,191,062
+100,463
| +2% | +$809K |
|
369
Cummins
CMI
$87.9B
| $50.4M | 0.06% |
+310,900
| New | +$48.2M |
|
370
J&J Snack Foods
JJSF
$1.66B
| $50.4M | 0.06% |
381,800
+29,700
| +8% | +$3.96M |
|
|
XEC
371
DELISTED
CIMAREX ENERGY CO
XEC
| $50.3M | 0.06% |
535,298
+473,600
| +768% | +$52.2M |
|
|
VVC
372
DELISTED
Vectren Corporation
VVC
| $49.9M | 0.06% |
854,400
-70,500
| -8% | -$4.23M |
|
373
Sinclair Inc
SBGI
$994M
| $49.8M | 0.06% |
1,515,177
+143,606
| +10% | +$5.17M |
|
374
Empire State Realty Trust
ESRT
$805M
| $49.8M | 0.06% |
2,398,300
-609,600
| -20% | -$12.8M |
|
375
RingCentral
RNG
$5.15B
| $49.7M | 0.06% |
1,359,800
-284,205
| -17% | -$9.4M |
|
Similar funds
Jim Simons's Q2 2017 Portfolio in Review
As of Q2 2017, Jim Simons held 3,586 positions worth $78.4B, up 9.5% from $71.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
Jim Simons deployed $4.59B of net new capital in Q2 2017, opening 398 new positions and adding to 1,648 existing holdings. Its largest new stake was Pfizer: 8,421,609 shares worth $268M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 15% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was Comcast, an estimated $263M trimmed.
- Jim Simons's largest Q2 2017 buy was Pfizer: 8,421,609 shares worth $268M.
- Jim Simons added most to Bristol-Myers Squibb in Q2 2017, an estimated $382M increase.
- Jim Simons's biggest Q2 2017 reduction was Comcast, cutting an estimated $263M.
- Jim Simons fully exited Booking.com in Q2 2017, selling an estimated $358M.
- Jim Simons's ten largest holdings make up 9% of its $78.4B portfolio in Q2 2017.
- Jim Simons opened 398 new positions and closed 418 in Q2 2017.
- Jim Simons's portfolio value rose 9.5% quarter-over-quarter to $78.4B.
Based on Renaissance Technologies's 13F filing for Q2 2017, filed 11 Aug 2017.